IMNN Imunon, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 749647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-4.9%
TTM EPS YoY60.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-448.6%
ROA-143.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets78.2%
Debt / equity0.00x
Current ratio1.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $500,000 | $500,000 |
| R&D expense | $7.78M | $11.64M | $11.29M | $11.73M | $10.62M |
| SG&A expense | $6.87M | $7.49M | $9.74M | $13.69M | $10.89M |
| Operating income | -$14.65M | -$19.13M | -$21.03M | -$24.92M | -$21.01M |
| Interest expense | — | — | $197,080 | $5.03M | $569,881 |
| Pretax income | $14.50M | $18.60M | -$20.80M | -$37.47M | -$22.15M |
| Income tax | — | — | -$1.28M | -$1.57M | -$1.38M |
| Net income | -$14.50M | -$18.62M | -$19.51M | -$35.90M | -$20.77M |
| EBITDA | -$14.36M | -$18.89M | -$20.78M | -$24.72M | -$20.30M |
| EPS (basic) | -6.83 | -16.94 | -2.16 | -5.03 | -3.83 |
| EPS (diluted) | -6.83 | -16.94 | -2.16 | -5.03 | -3.83 |
| Weighted avg. shares (diluted) | 2.12M | 1.10M | 9.05M | 7.14M | 5.43M |
| Balance sheet | |||||
| Cash & equivalents | $8.78M | $5.87M | $5.84M | $11.49M | $19.59M |
| Short-term investments | — | — | $9.86M | $21.23M | $29.81M |
| Current assets | $10.72M | $8.01M | $18.24M | $36.78M | $51.95M |
| PP&E, net | $529,936 | $541,272 | $751,906 | $548,301 | $477,011 |
| Total assets | $12.29M | $9.72M | $21.92M | $43.98M | $74.05M |
| Current liabilities | $4.62M | $4.79M | $7.39M | $10.04M | $6.77M |
| Long-term debt | — | — | — | $5.96M | — |
| Total debt | — | — | — | $5.96M | — |
| Total liabilities | $5.23M | $5.47M | $8.53M | $14.65M | $18.25M |
| Shareholders' equity | $7.06M | $4.24M | $13.39M | $29.33M | $55.80M |
| Net debt | — | — | — | -$5.53M | — |
| Shares outstanding | 3.42M | 966,712 | 9.40M | 7.44M | 5.77M |
| Cash flow statement | |||||
| Operating cash flow | -$13.90M | -$18.85M | -$19.02M | -$23.10M | -$16.22M |
| Capital expenditure | $280,572 | $29,541 | $451,759 | $267,800 | $311,613 |
| Free cash flow | -$14.18M | -$18.88M | -$19.47M | -$23.36M | -$16.54M |
| Investing cash flow | -$280,572 | $9.83M | $11.01M | $8.28M | -$30.12M |
| Financing cash flow | $17.09M | $9.06M | -$3.64M | $6.72M | $54.77M |
| Depreciation & amortization | $291,908 | $240,175 | $248,000 | $197,000 | $702,918 |
| Stock-based compensation | $127,374 | $477,256 | $759,013 | $2.67M | $3.76M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.